SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add	dress of Reporting	Person [*]	2. Issuer Name and Ticker or Trading Symbol <u>Aptevo Therapeutics Inc.</u> [APVO]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
(Last) 2401 4TH AV	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/28/2024	X Director 10% Owner X Officer (give title Other (specify below) President and CEO								
1,050			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street)				X Form filed by One Reporting Person								
SEATTLE	WA	98121		Form filed by More than One Reporting Person								
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication									
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									
		Table I - Non-D	erivative Securities Acquired, Disposed of, or Ben	eficially Owned								

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Form: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price			
Common Stock	01/28/2024		М		4,792	Α	(1)	44,929	D	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) Disp of (I	oosed D) tr. 3, 4	Expiration Date (Month/Day/Year) d		e Amount of			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Unit	(1)	01/28/2024		М			4,792	(2)	(2)	Common Stock	4,792	\$ <mark>0</mark>	0	D	

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, \$0.001 par value per share, of the Issuer on a one-for-one basis.

2. On January 29, 2021, the reporting person was granted 14,375 RSUs, vesting in three approximately equal annual installments beginning on January 28, 2022.

<u>/s/ SoYoung Kwon, Attorney-</u> <u>In -Fact</u> <u>01/30/2024</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.